Spots Global Cancer Trial Database for niraparib
Every month we try and update this database with for niraparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer | NCT03602859 | Ovarian Neoplas... Ovarian, Fallop... | Niraparib Dostarlimab (TS... Standard of car... Dostarlimab-Pla... Niraparib-Place... | 18 Years - | Tesaro, Inc. | |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | NCT04592237 | Aggressive Vari... Castration-Resi... Metastatic Pros... Metastatic Pros... Metastatic Pros... Stage IV Prosta... | Cabazitaxel Carboplatin Cetrelimab Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer | NCT04986371 | Epithelial Ovar... | Niraparib | 18 Years - | ChineseAMS | |
| Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | NCT03016338 | Endometrial Can... | Niraparib TSR-042 | 18 Years - | University Health Network, Toronto | |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients | NCT05898399 | Advanced Solid ... Metastatic Soli... | ART6043 Olaparib Niraparib Olaparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03586661 | Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Copanlisib Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | NCT05065021 | Ovarian Cancer Fallopian Tube ... Primary Periton... High Grade Sero... High Grade Endo... | Niraparib Dostarlimab Bevacizumab Paclitaxel | 18 Years - | University Health Network, Toronto | |
| Reirradiation and Niraparib in Patients With Recurrent Glioblastoma | NCT05666349 | Recurrent Gliob... | Niraparib Re-irradiation ... | 18 Years - | University College, London | |
| Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC | NCT04681469 | Head and Neck S... | Niraparib | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | NCT03025867 | Recurrent Ovari... | Niraparib | 18 Years - | Tesaro, Inc. | |
| Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR | NCT04295577 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Niraparib | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | NCT06433219 | Ovarian Cancer | Tuvusertib (M17... Niraparib Lartesertib (M4... | 18 Years - | EMD Serono | |
| Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | NCT03154281 | Breast Cancer Ovarian Cancer | niraparib everolimus | 18 Years - | Avera McKennan Hospital & University Health Center | |
| A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | NCT03840967 | Esophageal Canc... Gastric Cancer Adenocarcinoma | Niraparib | 18 Years - | Hoosier Cancer Research Network | |
| A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | NCT03840967 | Esophageal Canc... Gastric Cancer Adenocarcinoma | Niraparib | 18 Years - | Hoosier Cancer Research Network | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Study of M4344 in Combination With Niraparib | NCT04655183 | Advanced Solid ... Breast Cancer | Niraparib M4344 Niraparib M4344 Niraparib Niraparib | 18 Years - | EMD Serono | |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | NCT05672095 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Biopsy Biospecimen Col... Niraparib Questionnaire A... Selenium | 18 Years - | City of Hope Medical Center | |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes | NCT05694715 | Metastatic Soli... BRCA1 Mutation BRCA2 Mutation ATM Gene Mutati... PALB2 Gene Muta... | Niraparib Irinotecan | 18 Years - | University of California, San Francisco | |
| LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | NCT04762901 | Breast Cancer | Niraparib Doxorubicin Cyclophosphamid... Paclitaxel Pegfilgrastim Carboplatin | 18 Years - | Wake Forest University Health Sciences | |
| Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | NCT02354131 | Ovarian Cancer | Niraparib Bevacizumab | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer | NCT04986371 | Epithelial Ovar... | Niraparib | 18 Years - | ChineseAMS | |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | NCT03783949 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ganetespib Niraparib Carboplatin Paclitaxel Gemcitabine | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. | NCT05583799 | Ovarian Cancer | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | ||
| A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer | NCT05261269 | HER2-negative M... | DAN-222 Niraparib | 18 Years - | Dantari, Inc. | |
| Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer | NCT04837209 | Breast Cancer Triple Negative... | Niraparib Dostarlimab Radiation thera... | 18 Years - | Massachusetts General Hospital | |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | NCT03783949 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ganetespib Niraparib Carboplatin Paclitaxel Gemcitabine | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | NCT04267939 | Advanced Solid ... Ovarian Cancer | Elimusertib (BA... Niraparib | 18 Years - | Bayer | |
| Biomarker-based Study in R/M SCCHN | NCT03088059 | Carcinoma, Squa... | Afatinib Palbociclib standard of car... IPH2201 Durvalumab Niraparib INCAGN01876 | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib | NCT06037213 | Ovarian Cancer | 18 Years - | Peking Union Medical College Hospital | ||
| LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | NCT04762901 | Breast Cancer | Niraparib Doxorubicin Cyclophosphamid... Paclitaxel Pegfilgrastim Carboplatin | 18 Years - | Wake Forest University Health Sciences | |
| A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | NCT05021562 | Ovarian Cancer | Niraparib | - | Takeda | |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | NCT05187208 | Epithelial Ovar... Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... | Niraparib | 20 Years - | Seoul National University Hospital | |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | NCT04240106 | Breast Cancer Breast Cancer M... | Niraparib Aromatase Inhib... | 18 Years - | MedSIR | |
| Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | NCT05601440 | Breast Cancer | RP-6306 Gemcitabine Observation Niraparib Fulvestrant | - | Canadian Cancer Trials Group | |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | NCT02657889 | Neoplasms Triple Negative... Ovarian Cancer Breast Cancer Metastatic Brea... Advanced Breast... Stage IV Breast... Fallopian Tube ... Peritoneal Canc... | niraparib pembrolizumab | 18 Years - | Tesaro, Inc. | |
| Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | NCT03404960 | Pancreatic Aden... | Niraparib + Niv... Niraparib + Ipi... | 18 Years - | University of Pennsylvania | |
| Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy | NCT05412706 | Metastatic Colo... | Niraparib | 18 Years - | Ospedale Policlinico San Martino | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | NCT05076513 | Glioblastoma Glioblastoma Mu... Glioma GBM Glioma, Maligna... Glioblastoma Mu... | Niraparib Radiation thera... | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | NCT04673448 | Anatomic Stage ... Anatomic Stage ... BRCA-Associated... BRCA-Associated... Metastatic BRCA... Metastatic Brea... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Prim... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Br... Unresectable Fa... Unresectable Ma... Unresectable Ov... Unresectable Pa... Unresectable Pr... | Dostarlimab Niraparib | 18 Years - | University of Washington | |
| Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | NCT04493060 | Metastatic Panc... Stage IV Pancre... | Dostarlimab Niraparib | 18 Years - | Mayo Clinic | |
| Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | NCT05526989 | Penile Carcinom... | Dostarlimab Niraparib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | NCT04895046 | HRD Cholangiocarcin... Metastatic Canc... | Niraparib Dostarlimab Dostarlimab | 18 Years - | Hoosier Cancer Research Network | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | NCT03368729 | Metastatic Brea... HER2 Positive B... | Niraparib Trastuzumab | 18 Years - | University of Alabama at Birmingham | |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | NCT02854436 | Prostatic Neopl... | Niraparib | 18 Years - | Janssen Research & Development, LLC | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | NCT01905592 | Neoplasms, Brea... Carcinoma of Br... Human Epidermal... BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Neoplas... | niraparib Physician's cho... | 18 Years - | Tesaro, Inc. | |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma | NCT05455424 | Mesothelioma, M... | Niraparib Oral ... Active Symptom ... | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | NCT03748641 | Castration-Resi... | Niraparib Abiraterone Ace... Prednisone Placebo New Formulation... | 18 Years - | Janssen Research & Development, LLC | |
| Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | NCT03891615 | Lung Cancer | Niraparib Osimertinib | 18 Years - | Massachusetts General Hospital | |
| LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | NCT04762901 | Breast Cancer | Niraparib Doxorubicin Cyclophosphamid... Paclitaxel Pegfilgrastim Carboplatin | 18 Years - | Wake Forest University Health Sciences | |
| ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | NCT02044120 | Ewing Sarcoma | niraparib Temozolomide Irinotecan | 13 Years - | Sarcoma Alliance for Research through Collaboration | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | NCT06077877 | Neoplasms | GSK4524101 Niraparib | 18 Years - | GlaxoSmithKline | |
| Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | NCT05700721 | Brain Metastase... | Niraparib Dostarlimab | 18 Years - | M.D. Anderson Cancer Center | |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | NCT04030559 | ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CDK12 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... DNA Damage Resp... DNA Repair Gene... FANCA Gene Muta... FANCD2 Gene Mut... FANCL Gene Muta... GEN1 Gene Mutat... NBN Gene Mutati... Prostate Carcin... RAD51 Gene Muta... RAD51C Gene Mut... | Niraparib Niraparib Tosyl... Radical Prostat... | 18 Years - | University of California, Davis | |
| A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer | NCT05641506 | Ovarian Cancer | Yangzheng Xiaoj... Niraparib | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | NCT04947254 | Prostate Carcin... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IVA Prost... | Abiraterone Ace... Antiandrogen Th... Apalutamide Biopsy Niraparib Prednisone Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | NCT04240106 | Breast Cancer Breast Cancer M... | Niraparib Aromatase Inhib... | 18 Years - | MedSIR | |
| Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer | NCT05183984 | Ovarian Cancer | Chemotherapy Bevacizumab-Aww... Niraparib | 18 Years - 99 Years | ARCAGY/ GINECO GROUP | |
| Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer | NCT05442749 | Metastatic Panc... | Niraparib | 18 Years - | Centre Leon Berard | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | NCT02500901 | Metastatic Pros... | Enzalutamide Niraparib | 18 Years - | Hoosier Cancer Research Network | |
| A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | NCT05198804 | Ovarian Cancer Platinum-resist... Primary Periton... Fallopian Tube ... | ZN-c3 Niraparib | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency | NCT06237205 | Efficacy | Niraparib | 19 Years - | Korea University Anam Hospital | |
| A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer | NCT05261269 | HER2-negative M... | DAN-222 Niraparib | 18 Years - | Dantari, Inc. | |
| Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer | NCT03955471 | Ovarian Neoplas... | Niraparib Dostarlimab | 18 Years - | Tesaro, Inc. | |
| Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT04546373 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Niraparib | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab | NCT06141265 | Ovarian, Fallop... | Niraparib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | NCT05870761 | Recurrent Endom... | Biospecimen Col... Computed Tomogr... Dostarlimab Magnetic Resona... Niraparib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months | NCT04826198 | Ovarian Cancer | AsiDNA Niraparib Olaparib Rucaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC | NCT04313504 | Head and Neck C... | Niraparib Dostarlimab | 18 Years - | University of Cincinnati | |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | NCT03895788 | Ovarian Cancer | niraparib Brivanib | 18 Years - | Hunan Cancer Hospital | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
